2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-147406
    Tonlamarsen 2589926-20-3
    Tonlamarsen is a angiotensinogen synthesis reducer, with antihypertensive activity.
    Tonlamarsen
  • HY-14744B
    Levamlodipine hydrochloride 865430-76-8 98%
    Levamlodipine hydrochloride (Levoamlodipine hydrochloride) is a dihydropyridine calcium channel blocker. Levamlodipine hydrochloride reduces the inflow of calcium ions by blocking L-type calcium channels on vascular smooth muscle cells, thereby leading to vasodilation, lower blood pressure and lighten the burden on the heart. Levamlodipine hydrochloride has activity to lower blood pressure and relieve angina. The binding properties of Levamlodipine hydrochloride to human serum albumin (HSA) contribute to the study of drug transport and release mechanisms in the body.
    Levamlodipine hydrochloride
  • HY-14744C
    Levamlodipine hydrobromide 865430-78-0 98%
    Levamlodipine hydrobromide is the besylate hydrobromide salt form of Levamlodipine (HY-14744). Levamlodipine hydrobromide is an orally active calcium channel blocker with antioxidant and vasodilatory properties. Levamlodipine hydrobromide can reduce serum malondialdehyde (MDA) levels, increase superoxide dismutase (SOD) activity, and improve oxidative stress. Levamlodipine hydrobromide can be used for research on vascular dementia, hypertension, and cerebrovascular diseases.
    Levamlodipine hydrobromide
  • HY-147502
    Vin-C01 23173-26-4 98%
    Vin-C01 is a potent pancreatic β-cells protective agent with an EC50 of 0.22 μM. Vin-C01 effectively promotes β-cell survival and protects β-cells from STZ (HY-13753)-induced apoptosis. Vin-C01 can be used for type 2 diabetes mellitus research.
    Vin-C01
  • HY-147503
    Vin-F03 2180917-11-5 98%
    Vin-F03 is a potent pancreatic β-cells protective agent with an EC50 of 0.27 μM. Vin-F03 effectively promotes β-cell survival and protects β-cells from STZ (HY-13753)-induced apoptosis. Vin-F03 can be used for type 2 diabetes mellitus research.
    Vin-F03
  • HY-147574
    Axl-IN-7 1770821-83-4 98%
    Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used for Axl-related diseases research, for example cancers (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors), renal disease, immune system disorders, and cardiovascular disease.
    Axl-IN-7
  • HY-147751
    APJ receptor agonist 6 1965244-85-2 98%
    APJ receptor agonist 6 (compound 9) is a potent APJ (apelin receptor) agonist, with Ki of 1.3 μM. APJ receptor agonist 6 has EC50 values of 0.070 , 0.097, and 0.063 μM for calcium, cAMP, and β-arrestin, respectively.
    APJ receptor agonist 6
  • HY-147910
    Carpro-AM1 2499489-76-6 98%
    Carpro-AM1 is a dual-acting FAAH/substrate-selective COX inhibitor with an IC50 value of 94 nM for FAAH.
    Carpro-AM1
  • HY-148000
    sEH inhibitor-6 1205963-04-7 98%
    sEH inhibitor-6 (Compound 3g) is a soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 0.5 nM.
    sEH inhibitor-6
  • HY-148144
    Clobutinol 14860-49-2 98%
    Clobutinol is a compound that has anti-tussive effects. Clobutinol affects heart rate and blood pressure, it can be used for cough related research.
    Clobutinol
  • HY-148292
    C16-Sphingosine-1-phosphate 709026-60-8 98%
    C16-Sphingosine-1-phosphate is a derivative of Sphingosine-1-phosphate and also an endogenous ligand for the EDG/S1P receptor. C16-Sphingosine-1-phosphate can be used in the research of angiogenesis, inflammation, and cardiovascular diseases.
    C16-Sphingosine-1-phosphate
  • HY-148300
    AR-C66096 145783-24-0 98%
    AR-C66096 is a potent and selective antagonist of the Gi-coupled P2Y12 receptor. AR-C66096 suppresses platelet thrombus stability under physiological flow conditions. AR-C66096 inhibits ADP-induced aggregation in whole blood aggregometry. AR-C66096 can be used for antithrombotic research.
    AR-C66096
  • HY-148312
    Sirtuin modulator 4 327104-77-8 98%
    Sirtuin modulator 4 (compound 12) is a sirtuin modulator. Sirtuin modulator 4 shows inhibitory effect to SIRT1 with an EC50 value of 51-100 μM. Sirtuin modulator 4 may be used for the research of increasing the lifespan of a cell, and preventing a wide variety of diseases and disorders including, for example, diabetes, obesity, neurodegenerative diseases, cardiovascular diseases, inflammation and cancer.
    Sirtuin modulator 4
  • HY-14839A
    Evatanepag sodium 223490-49-1 98%
    Evatanepag sodium is a non-prostanoid, potent and selective EP2 receptor agonist. Evatanepag sodium can induce local bone formation in vivo. Evatanepag sodium can be used in the research of fractures, bone defects, asthma.
    Evatanepag sodium
  • HY-148475
    (R)-SEMBL 1443449-07-7 98%
    (R)-SEMBL (compound 1B) is a potent NF-κB inhibitor. (R)-SEMBL can be used for the research of cancer, inflammation, autoimmune diseases, diabetes and diabetes complications, infections, cardiovascular disease and defective reperfusion injury.
    (R)-SEMBL
  • HY-148524
    β2AR/M-receptor agonist-1 2230520-62-2 98%
    β2AR/M-receptor agonist-1 (example 131) is a muscarinic antagonist and β2 adrenoceptor agonist (MABA). β2AR/M-receptor agonist-1 shows potency to β2 adrenoceptor with an EC50 value of 9.2 nM. β2AR/M-receptor agonist-1 also has potency to muscarinic receptor with a Ki value of 30.2 nM. β2AR/M-receptor agonist-1 shows MABA potency with an EC50 value of 4.0 nM.
    β2AR/M-receptor agonist-1
  • HY-148525
    PF-4348235 1017857-38-3 98%
    β2AR/M-receptor agonist-2 (compound 15) is a muscarinic antagonist and β2 adrenoceptor agonist (MABA). β2AR/M-receptor agonist-2 shows potency to β2 adrenoceptor with an EC50 value of 3.7 nM. β2AR/M-receptor agonist-2 also has potency to human cloned M3 receptor with a Ki value of 0.73 nM. β2AR/M-receptor agonist-2 is a potent bronchodilator, it can be used for the research of chronic obstructive pulmonary disease (COPD).
    PF-4348235
  • HY-148573
    sEH inhibitor-14 2890221-26-6 98%
    sEH inhibitor-14 (compound 33) is a benzoxazolone-5-urea analogue. In addition, sEH inhibitor-14 is a soluble Epoxide Hydrolase (sEH) inhibitor (IC50=0.39 nM).
    sEH inhibitor-14
  • HY-148625
    PDE9-IN-2 917089-10-2 98%
    PDE9-IN-2 (compound 6) is a PDE9 inhibitor that improves heart failure.
    PDE9-IN-2
  • HY-148651
    CDK2-IN-15 1219915-83-9 98%
    CDK2-IN-15 (Compound 19) is an inhibitor of CDK2 with an IC50 of 2.9 μM. CDK2-IN-15 can be used for cancer research.
    CDK2-IN-15
Cat. No. Product Name / Synonyms Application Reactivity